Theravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Theravance Biopharma (NASDAQ: TBPH) announced its participation in the upcoming H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Theravance Biopharma (NASDAQ: TBPH) announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference in New York City. CEO Rick Winningham will engage in a Fireside Chat on September 9, 2025, at 1:30 PM EDT.
The company will offer in-person meeting opportunities for interested investors through H.C. Wainwright representatives. A live webcast will be available online, with a replay accessible on Theravance's website for 30 days following the event.
Details
News Market Reaction – TBPH
On Sep 2, the day this news came out, TBPH closed 0.29% below the previous close.
Data tracked by StockTitan Argus for the Sep 2 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Rick Winningham, CEO, will participate in a Fireside Chat on Tuesday, September 9 at 1:30 PM EDT (10:30 AM PDT / 6:30 PM IST).
Management will be hosting in-person meetings during the event. Interested investors should contact their H.C. Wainwright representative to request a meeting.
A live webcast of the event may be accessed here or on the "Events and Presentation" page under the Investors section on Theravance.com. A replay of the webcast will be archived on the Company's website for 30 days.
About Theravance Biopharma
Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.
For more information, please visit www.theravance.com.
THERAVANCE BIOPHARMA®, THERAVANCE® and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).
YUPELRI® is a registered trademark of Viatris Specialty LLC. Trademarks, trade names or service marks of other companies appearing on this press release are the property of their respective owners.
Contact:
investor.relations@theravance.com
650-808-4045
View original content to download multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-present-at-the-hc-wainwright-27th-annual-global-investment-conference-302543498.html
SOURCE Theravance Biopharma, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.